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Genome-wide association studies (GWAS) have identified ~20 melanoma susceptibility loci,
most of which are not functionally characterized. Here we report an approach integrating
massively-parallel reporter assays (MPRA) with cell-type-specific epigenome and expression
quantitative trait loci (eQTL) to identify susceptibility genes/variants from multiple GWAS
loci. From 832 high-LD variants, we identify 39 candidate functional variants from 14 loci
displaying allelic transcriptional activity, a subset of which corroborates four colocalizing
melanocyte cis-eQTL genes. Among these, we further characterize the locus encompassing
the HIV-1 restriction gene, MX2 (Chr21q22.3), and validate a functional intronic variant,
rs398206. rs398206 mediates the binding of the transcription factor, YY1, to increase MX2
levels, consistent with the cis-eQTL of MX2 in primary human melanocytes. Melanocyte-
specific expression of human MX2 in a zebrafish model demonstrates accelerated melanoma
formation in a BRAFV600E background. Our integrative approach streamlines GWAS follow-
up studies and highlights a pleiotropic function of MX2 in melanoma susceptibility.
https://doi.org/10.1038/s41467-020-16590-1 OPEN
1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA. 2 Stem Cell Program and Division of Hematology/
Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, MA 02115, USA. 3 Department of Molecular Biology, Faculty of Science,
Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University Nijmegen, 6525 XZ Nijmegen, The Netherlands. 4 Université de Paris,
UMRS-1124, Institut National de la Santé et de la Recherche Médicale (INSERM), F-75006 Paris, France. 5 Leeds Institute for Data Analytics, School of
Medicine, University of Leeds, Leeds LS2 9JT, UK. 6 Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles,
Los Angeles, CA 90024, USA. 7 Genome Modification Core, Frederick National Lab for Cancer Research, National Cancer Institute, Frederick, MD 21701,
USA. 8Department of Medicine, Imperial College London, London SW7 2BU, UK. 9 Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane,
QLD 4006, Australia. 10These authors contributed equally: Jiyeon Choi, Tongwu Zhang. ✉email: kevin.brown3@nih.gov
NATURE COMMUNICATIONS |         (2020) 11:2718 | https://doi.org/10.1038/s41467-020-16590-1 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
A series of genome-wide association studies (GWAS) overthe past decade has identified about twenty genomic lociassociated with cutaneous melanoma1–10, highlighting the
genetic contribution to melanoma susceptibility in the general
population. Some of these loci represent genes or regions impli-
cated in melanoma-associated traits e.g., pigmentation pheno-
types11–15 and nevus count5,16,17. Other than these loci, however,
underlying mechanisms of genetic susceptibility to melanoma in
the general population is less well understood. For a small
number of these loci, extensive characterization of susceptibility
genes and variants under the GWAS peaks have led to insights
into molecular pathways underlying melanoma susceptibility.
PARP1, located in the Chr1q42.1 melanoma locus8, was shown to
be a susceptibility gene that has tumor-promoting roles in early
events of melanomagenesis through its regulation of melanocyte
master transcription factor and oncogene, MITF18, while a
functional variant at a multi-cancer locus on Chr5p15.33 was
characterized highlighting the role of TERT in cancer suscept-
ibility including in melanoma19. Still, the molecular mechanisms
underlying the majority of common melanoma risk loci remain
unexplained.
Recent advances in sequencing technologies have enabled a
number of classical molecular assays to be conducted at a large
scale. Massively Parallel Reporter Assays (MPRA) scale up con-
ventional luciferase reporter assays for testing transcriptional
activities of DNA elements, facilitating evaluation of tens of thou-
sands of different short sequences at the same time in cells, which
are then deconvoluted by massively parallel sequencing20–22.
Incorporation of this approach is particularly attractive for GWAS
functional follow-up studies, as (1) linkage disequilibrium (LD)
limits statistical fine-mapping and leaves numerous variants as
potential functional candidates, and (2) many trait-associated var-
iants are hypothesized to contribute to allelic gene expression
through cis-regulatory mechanisms that can be tested by reporter
assays. Therefore, direct assessment of allelic differences in tran-
scriptional regulation could help prioritize likely functional variants
among multiple variants tied by LD. For example, a recent study
adopted MPRA to test 2756 variants from 75 GWAS loci for red
blood cell traits and identified 32 functional variants from 23 loci20.
In addition, expression quantitative trait loci (eQTL) analysis
can be a powerful approach for identifying susceptibility genes
from GWAS loci, as it informs on genes for which expression
levels are correlated with trait-associated variants. While there are
a number of publicly available eQTL datasets using tissues
representing different human organs including those through the
GTEx project23, most of them are based on bulk tissue samples
(e.g., skin tissues) as opposed to individual cell types. Importantly,
melanomas arise from melanocytes, but they account for less than
5% of a typical skin biopsy. To dissect cell-type specific gene
expression regulation implicated in melanoma predisposition, a
melanocyte eQTL dataset using primary cultures of melanocytes
from 106 individuals was established and mapped six melanoma
GWAS loci (30% of all the loci) to melanocyte eQTLs24. This
dataset identified more candidate susceptibility genes than using
eQTLs from datasets of larger sample size generated from bulk
skin tissues, other tissue types from GTEx, and melanoma
tumors24, highlighting the utility of cell-type specific eQTL
dataset for functional follow-up of GWAS regions.
In this study, we combine MPRA and cell-type specific mela-
nocyte eQTL to scale up the functional annotation process for
melanoma GWAS loci and nominate the best candidates for
testing in a zebrafish model. Using our approach we identify a
functional risk variant that increases the level of an HIV-1
restriction gene, MX2, in cells of melanocytic lineage; subsequent
expression of MX2 in melanocytes of a zebrafish melanoma
model accelerates melanoma formation.
Results
MPRA identified melanoma-associated functional variants. To
identify functional melanoma-associated variants displaying
allelic transcriptional function, we used the MPRA approach.
Among 20 genome-wide significant melanoma loci from the most
recent GWAS meta-analysis1, we prioritized 16 loci where a
potential cis-regulatory mechanism could be hypothesized,
excluding four pigmentation-associated loci previously explained
by functional protein coding variants (MC1R, SLC45A2, and
TYR11–14) or shown not to be expressed in melanocytes (ASIP15).
To comprehensively analyze genetic signals from these loci, we
then performed statistical fine-mapping using the HyperLasso25
approach. The fine-mapping nominated additional independent
signals (Supplementary Table 1), from which we selected 30
variants, adding to the 16 lead SNPs from the initial meta-analysis
results1. To prioritize melanoma-associated variants to test by
MPRA, we first selected 2748 variants that are in LD (r2 > 0.4)
with these 46 primary and secondary lead SNPs (Methods; Sup-
plementary Fig. 1; Supplementary Table 2). Among them, we
further prioritized 832 variants that overlap potentially functional
melanoma-relevant genomic signatures, namely, open chromatin
regions and promoter/enhancer histone marks in primary mela-
nocytes and/or melanoma short term cultures26 (Supplementary
Data 1; Supplementary Table 3; Methods; www.encodeproject.
org; www.roadmapepigenomics.org). We then constructed MPRA
libraries for these 832 variants using methods adopted from
previous studies20–22,27. A 145 bp genomic sequence encom-
passing the risk or protective allele of each variant was tested for
their potential as an enhancer or promoter element in luciferase
constructs. For each variant, a scrambled sequence for its core 21
bases was also tested as a null (Fig. 1a; Methods). Transcribed
output of tag (barcode) sequences associated with each tested
DNA element were then measured by sequencing, after trans-
fections into a melanoma cell line (UACC903) to represent
melanoma-specific trans-acting factors and the HEK293FT cell
line to obtain maximum transfection efficiency. From these data,
we initially observed significantly high correlation of transcrip-
tional activities among replicates, and further applied a con-
servative quality control measure for downstream analyses
(Methods; Supplementary Figs. 2–6; Supplementary Table 4).
To nominate variants displaying allelic transcriptional activity,
we focused on those displaying significant difference between two
alleles (FDR < 0.01; two-sided Wald test with robust sandwich
type variance estimate; multiple comparisons adjusted using
Benjamini & Hochberg method), and then further selected those
with either allele displaying a significant departure from the null
(scrambled core sequence; FDR < 0.01) (Supplementary Fig. 2).
After applying these cutoffs, 39 of the 832 tested variants (~4.7%)
qualified as displaying allelic transcriptional activity in the
UACC903 melanoma cell dataset alone, as well as in the
combined total dataset (Methods; Supplementary Fig. 7a; Sup-
plementary Table 5). These candidate functional variants are
from 14 melanoma GWAS loci with 1–9 variants per locus
(median 1.5 variants), demonstrating that MPRA narrowed down
functional candidate variants to a considerably small number
from tens to hundreds of high-LD variants in most of the loci
(Fig. 1b; Supplementary Table 6; Supplementary Fig. 8). Tran-
scriptional activities of these 39 variants were significantly higher
than those of negative controls (8 variants of high LD with the
lead SNP but located in non-DHS/non-promoter/enhancer
histone mark in melanocytes/melanoma cells; P < 2.2e−16, effect
size= 0.137; Mann–Whitney U test; Supplementary Fig. 7b),
as well as the rest of the variants (non-significant variants; P <
2.2e−16, effect size= 0.109). These 39 variants displayed a
modest 1.13 to 3.49-fold (median 1.26-fold) difference in
transcriptional activity between two alleles consistent with subtle
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effects on risk observed for common cancer-associated variants
(UACC903 cells; Supplementary Table 5). We then asked if the
observed allelic differences from MPRA are in part due to
differential binding of transcription factors. For this, we predicted
allelic transcription factor binding affinity of each tested variant
using motifbreakR28 and subsequently correlated the predicted
allelic binding scores with the allelic transcriptional activities
measured from MPRA. Notably, the MPRA-significant variants
displayed a higher level of correlation compared to that of non-
significant ones, shown by a larger Pearson r (Pearson r= 0.24 vs.
−0.023; Supplementary Fig. 9a), while the P-values for the both
tests are not significant (P= 0.149 and 0.556, respectively). We
then asked if MPRA-significant variants are enriched in credible
causal variants or those with higher probability scores from a
Bayesian fine-mapping approach. For this we performed
statistical fine-mapping of melanoma GWAS data using PAIN-
TOR29 while integrating primary melanocyte-specific functional
annotations (Methods). When overlaid with the fine-mapping
results, the 39 significant MPRA variants (FDR < 0.01) indeed
displayed the highest median probability score compared to other
variant groups with varying FDR cutoffs, which was a 2.12-fold
enrichment over all the tested variants with probability scores
(Supplementary Fig. 9b). These data demonstrated that MPRA
can quickly narrow down to a small number of plausible
functional candidate variants from tens to hundreds of high-LD
variants from melanoma GWAS loci by measuring allelic
transcriptional activity.
eQTL prioritized functional candidates in four melanoma loci.
To prioritize functional variants that contribute to melanoma risk
through regulation of nearby gene expression, we turned to cell-
type specific melanocyte eQTL data from 106 individuals24.
597,335 significant cis-eQTL SNPs (+/−1 Mb of TSS, FDR < 0.05,
not LD-pruned) were identified in this dataset, with 6 of 20
melanoma GWAS loci displaying significant co-localization/
TWAS24. For the purpose of nominating the most plausible
candidates for functional follow-up, we mainly focused on the five
of these six loci with melanocyte eQTL support (1q21.3, 1q42.12,
2q33-q34, 21q22.3, and 22q13.1) that were also tested in our
MPRA. While there were initially 17 to 116 eQTL variants per
locus at a genome-wide significant level, MPRA further narrowed
them down to 3 to 9 functional variants in four loci based on
transcriptional activity (Supplementary Table 6). Among them, a
total of nine variants from four loci displayed a consistent
direction between MPRA and eQTL, in which the direction of
allelic expression of local genes matches those of MPRA allelic
transcriptional activity (Supplementary Table 6; Supplementary
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Fig. 1 MPRA identified 39 functional variants from 16 melanoma GWAS loci. a MPRA workflow. Oligo libraries were synthesized using 145 bp of
sequence encompassing each variant with risk or protective alleles or a scrambled sequence for core 21 bases in both forward and reverse directions, that
was flanked by enzyme recognition sites and sequencing primer sequences, as well as 10 bp barcodes (10 tags per unique sequence). Libraries were cloned
into luciferase constructs with or without a minimal TATA promoter. Cloned libraries were then transfected into HEK293FT cells or UACC903 melanoma
cells to generate expressed RNA tag libraries. Both input DNA and RNA libraries were sequenced to assess the tag counts associated with the test
sequences. Luc: luciferase gene, AAAAA: poly-A tail. b Volcano plots of MPRA results for each melanoma GWAS locus. Inverse P-values and effect sizes
of allelic difference from UACC903 transfections are shown for each of the 16 loci tested. A two-sided Wald test with robust sandwich type variance
estimate was used. Multiple comparisons were adjusted using the Benjamini and Hochberg method. Dashed horizontal lines indicate the FDR 1% cutoff for
allelic difference in the UACC903 set. The most significant variant from each locus is labeled. Putative function of 39 significant MPRA variants are shown
as activator (red circle), repressor (blue circle), or both (purple circle) (expression levels of either allele is higher, lower, or higher and lower than those of
scrambled sequence, respectively). Gray variants above the FDR 1% cutoff are those that failed additional criteria (allelic difference in the combined data or
significant departure from the scrambled control). No significant variants were identified from the loci on Chr6p22.3 and Chr7p21.1. Source data are
provided as a Source Data file.
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Fig. 9c). Namely, two MPRA-significant variants (rs2864871 and
rs6700022) from the locus on chromosome band 1q21.3 were
significant eQTLs for CTSS in melanocytes, where lower CTSS
levels were correlated with melanoma risk. Similarly, two to three
variants each (rs2349075, rs529458487, rs398206, rs408825,
rs4383, rs4384, and rs6001033) from three other loci (2q33-q34,
21q22.3, and 22q13.1) also overlapped with melanocyte eQTLs,
where lower CASP8, higher MX2, and higher MAFF levels were
correlated with melanoma risk, respectively (Supplementary
Table 7). For 1q42.12, none of the eQTL significant variants
passed the MPRA significance cutoff, and therefore were not
prioritized. Thus, by combining MPRA and cell-type specific
melanocyte eQTL, we efficiently prioritized candidate functional
variants and susceptibility genes from multiple melanoma
GWAS loci.
MX2 is a susceptibility gene in the 21q22.3 melanoma locus. To
validate the efficiency of our prioritization scheme, we performed
a thorough validation and functional characterization for one of
the four loci with combined MPRA and melanocyte eQTL sup-
port. We chose the locus on 21q22.3, where MPRA identified the
most significant variant. In this locus, twenty-two variants were
originally tested in MPRA (Supplementary Table 8), nineteen of
which are located in the first intron of the MX2 gene (Fig. 2a),
and the remaining three upstream. Of these, three variants were
significant in MPRA, and rs398206, in particular, (Fig. 2a, shown
in magenta) displayed the lowest P-value of all 832 tested var-
iants. rs398206 displayed a strong transcriptional activator
function (1.7 to 4.3-fold above the scrambled sequence), as well as
significant allelic difference, where the melanoma risk-associated
A allele drove significantly higher luciferase expression than
protective C allele (3.1-fold in UACC903 cells, FDR= 5.6e−206;
Fig. 2b). Subsequent individual luciferase assays using the same
145 bp sequence in two melanoma cell lines validated this finding
(2.7 to 5.0-fold allelic difference, P= 1.1e−6–5.2e−11; two-tailed,
unpaired t-test assuming unequal variance; Fig. 2c; Supplemen-
tary Fig. 9d). rs398206 was also a significant eQTL for levels of
MX2 gene expression in primary melanocytes, where the mela-
noma risk-associated A allele is correlated with higher MX2
expression (Slope= 0.70, P= 6.6e−15; linear regression; Fig. 2d).
While melanocyte eQTL consistently identified MX2 as the
best candidate susceptibility gene at the 21q22.3 melanoma
locus24, we further interrogated eQTL data from melanocytes and
44 GTEx tissue types, to comprehensively assess potential
melanoma susceptibility gene(s) in this locus. When we inspected
eQTL data from 44 GTEx tissue types, rs398206 was a significant
eQTL for MX2 in five other tissue types (testis, transformed skin
fibroblasts, ovary, tibial nerve, and whole blood) but no other
gene displayed a genome-wide significant eQTL with rs398206
(using a nominal P-value threshold set for each gene based on a
genome-wide empirical P-value as defined by GTEx V6p; GTEx
portal; https://gtexportal.org).
As the melanocyte cis-eQTL analyses used for the above
assessments were limited to the genes in +/−1Mb of the tested
variants24, we explored if rs398206 is a marginal eQTL for any
gene in the topologically-associated domain (TAD) to account for
potential gene regulation mediated by chromatin looping
typically occurring within this physical domain. From the
genomic interval defined as the TAD encompassing rs398206
(chr21:42,480,000–44,320,000; hg19; retrieved from Hi-C data of
SKMEL5 melanoma cell line generated for ENCODE dataset via
http://promoter.bx.psu.edu/hi-c/), a total of 21 genes were
significantly expressed in melanocytes, for which eQTL analyses
were performed. The results demonstrated that MX2 displayed
the most significant eQTL with rs398206 (P= 6.6e−15; linear
regression), while none of the other genes in the TAD displayed
even a marginally significant eQTL after adjusting for multiple
testing (Bonferroni-corrected cutoff at P < 0.0024 for 21 genes;
Supplementary Table 9). These data determined that MX2 is the
most likely susceptibility gene at the 21q22.3 melanoma
susceptibility locus.
To complement the eQTL data, we also assessed allele-specific
expression (ASE) of MX2 in melanocytes. rs398206 is located in
the 5’ UTR region of an alternative MX2 transcript isoform
(ENST00000543692; Supplementary Fig. 10a), the expression
levels of which are correlated with the most abundant full-length
transcript in melanocytes (ENST00000330714; Pearson r= 0.69,
P= 1.63e−16; Supplementary Fig. 11). RNA sequencing data
from our previous study did not find genome-wide significant
ASE for any melanoma-associated SNP (GWAS P < 5e−8)
residing in the transcribed region of MX224, partly due to low
sequence coverage of this transcript that is expressed at a low
level. To thoroughly examine allele-specific expression in this
region, we genotyped rs398206 in melanocyte cDNA using a
Taqman genotyping assay that recognizes both genomic DNA
and cDNA. The results demonstrated an over-representation of A
allele-bearing transcripts in 27 heterozygous individuals, when
the allelic ratio in cDNA was normalized to those in genomic
DNA (One-sample Wilcoxon test, P= 2.49e−5; Supplementary
Fig. 12). These data are consistent with the eQTL data, where the
risk-associated A allele is correlated with higher MX2 expression.
To thoroughly investigate possible mechanisms of allelic MX2
expression in relation to rs398206, we performed additional QTL
analyses in melanocytes addressing alternative modes of gene
regulation, including splice-QTL (sQTL) and DNA methylation
QTL (meQTL). sQTL analyses using LeafCutter30 suggested that
the main effect of the MX2 eQTL was not driven by alternative
isoforms or splicing events (Supplementary Fig. 10b–f; Supple-
mentary Note). meQTL analysis, on the other hand, identified a
significant meQTL for rs398026 at a CpG probe near the MX2
canonical promoter, where the melanoma risk-associated A allele
is correlated with lower CpG methylation, which is consistent
with higher expression of the full-length isoform (Supplementary
Fig. 13). Two other CpG probes in the first intron of MX2 (closer
to rs398206) also displayed significant meQTLs for rs398206 in
melanocytes, where higher CpG methylation is correlated with
the risk A allele. These observations are consistent with the
previous findings that DNA methylation in promoters is
negatively correlated with gene expression, while that of
transcribed regions is positively correlated with gene expres-
sion31–35. Taken together, eQTL, sQTL, and meQTL data are
consistent with the hypothesis that MX2 full-length transcript
mainly accounts for the eQTL at rs398206 in melanocytes
through a transcriptional mechanism.
rs398206 regulates MX2 levels via allelic binding of YY1. To
identify protein factors mediating the allelic difference observed
in MPRA, we performed comparative mass-spectrometry using a
21 bp DNA probe encompassing rs398206 with A or C alleles and
nuclear extract from the UACC903 melanoma cell line (Fig. 3a).
Among the proteins displaying allelic binding, the most promi-
nent A-allele preferential binding was shown for Yinyang-1
(YY1), a ubiquitous transcription factor having roles in devel-
opment and cancer36, as well as in pigmentation pathways of
melanocytes37. Sequence-based motif prediction was also con-
sistent with this finding, indicating that the sequence around
rs398206 forms a consensus binding site for YY1 favoring the A-
allele (Fig. 3b). Subsequent electrophoretic mobility shift assays
(EMSAs) validated that this A-allele-preferential binding of
nuclear proteins is sequence-specific, as shown by competition
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Fig. 2 rs398206 is a functional cis-regulatory variant and a significant cis-eQTL for MX2 levels in melanocytes. a Variants that were tested in MPRA
from the Chr21q22.3 melanoma locus are shown relative to the genomic position ofMX2. Only the 19 variants located in the first intron ofMX2 coming from
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1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots. Density is reflected in the width of the shape.
c Individual luciferase activity assays of 145 bp sequences encompassing rs398206 is shown for UACC903. pGL4.23 construct including minimal TATA
promoter was used. One representative set is shown from three biological replicates. Mean with SEM, n= 6. All constructs are significantly higher than
pGL4.23 (TATA) control (P < 0.0001, two-tailed, unpaired t-test assuming unequal variance). d eQTL plot of MX2 levels in primary melanocytes in relation
to rs398206 is shown for three genotype groups. Center lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times
the interquartile range from the 25th and 75th percentiles. P-value and slope were derived from linear regression with no multiple-testing correction applied.
Source data are provided as a Source Data file.
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with unlabeled probes (Fig. 3c). Antibody super-shift demon-
strated that YY1 is present in this subset of allelic-binding pro-
teins (Fig. 3c), which was further validated by EMSAs with
purified recombinant YY1 protein (Fig. 3c, d). We subsequently
performed chromatin immunoprecipitation (ChIP) using anti-
YY1 antibody and scanned a ~5Mb genomic region encom-
passing rs398206 in three melanoma cell lines representing each
genotype of rs398206 (AA, AC, and CC). We observed prominent
enrichment of YY1 binding on top of rs398206 in the AA cell line,
a weaker but clear enrichment in the AC line, and even weaker
binding enrichment over rs398206 in the CC line (Fig. 4a; Sup-
plementary Fig. 14). Given that differences between cell lines (e.g.,
DNA copy number differences, accessibility of chromatin in the
region encompassing rs398206, YY1 levels, and variability in
formaldehyde fixing and chromatin shearing efficiency) may also
contribute to differential YY1 binding, we also assessed allele-
specific YY1 binding in the heterozygous AC cell line
(UACC647). We performed genotyping of rs398206 using the
DNA fragments pulled down by anti-YY1 antibody. DNA frag-
ments pulled down using YY1 antibody displayed a significant
enrichment of A allele (Mann-Whitney U test, P= 9.1e−3), while
genomic DNA and serial-diluted input DNA displayed equivalent
signal from both A and C alleles, indicating clear A-allele pre-
ferential binding of YY1 in melanoma cells (Fig. 4b, c).
Based on this strong allelic YY1 binding, we next asked if YY1
regulates endogenous MX2 expression levels. siRNA knockdown
of YY1 in the UACC903 melanoma cell line demonstrated a weak
but consistent reduction of MX2 levels by four different sets of
siRNAs (14–32% decrease, P= 1.5e−3–1.9e−5, one-sample
Wilcoxon test; Fig. 5a; Supplementary Fig. 15a) indicating a
regulation of MX2 levels by YY1. To further determine if the
genomic region encompassing rs398206 regulates endogenous
MX2 levels, we targeted this region by CRISPRi using dCAS9-
KRAB-MeCP238 in the same melanoma cell line. Four gRNAs
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targeting the genomic regions either directly overlapping
rs398206 (gRNA 1, 3, and 4) or ~25 bp upstream (gRNA 2)
resulted in 61–82% reduction inMX2 expression levels (P= 2.05e
−4–3.19e−4, one-sample Wilcoxon test; Fig. 5b), while the same
gRNAs do not have effect on nearby MX1 expression
(Supplementary Fig. 15b). As rs398206 is located in the intronic
region of MX2, it is formally possible that some of the effect on
MX2 expression could be due to physical blocking of passage of
transcriptional machinery by the dCAS9-KRAB-MeCP2 system.
CRISPRi using dCAS9 without the transcriptional repressor
MX2
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elements, however, displayed little or no effect on MX2
expression, which is consistent with the CRISPRi effect on MX2
being mainly transcriptional (Supplementary Fig. 15c–e).
To identify additional support for rs398206 regulating MX2 via
YY1, we examined available chromatin interaction data involving
YY1. Notably, YY1 was recently shown to mediate chromatin
looping and contribute to interactions between gene promoters
and enhancers within TADs39. Given this, we examined YY1-
mediated chromatin interaction around the genomic region
encompassing rs398206 in these published Hi-ChIP data using
YY1 antibody. In the human colorectal carcinoma cell line,
HCT116, the 5Kb bin harboring rs398206 displayed a strong
interaction with the adjacent bin encompassing MX2 promoter
area39 (PET count= 18, P= 2.27e−80, hypergeometric test;
Supplementary Fig. 16). Together these data determined that
rs398206 is a functional variant regulating MX2 expression via
differential YY1 binding in the Chr21q22.3 melanoma locus.
MX2 accelerates melanoma formation in zebrafish. MX2 is best
known for its function in innate immunity as an HIV-1 restric-
tion gene40,41. In GTEx tissue types, the highest MX2 expression
levels are observed in EBV-transformed lymphocytes, whole
blood, and spleen, reflecting its main role in innate immune
response as an interferon-stimulated gene (GTEx portal; https://
gtexportal.org). On the other hand, a previous study also
demonstrated that MX2 has cell-autonomous function in the
proliferation of HeLa cells without IFNα-mediated induction42.
In our primary melanocyte dataset, MX2 is expressed at a rela-
tively high level (median expression ranked at top 26.5% of all
expressed genes) without IFNα stimulation. To assess co-
expressed genes and enriched pathways in melanocytes expres-
sing MX2 at a higher level, we profiled differentially expressed
genes between MX2-high (top 25%; n= 28) and MX2-low (bot-
tom 25%; n= 28) melanocytes from 106 individuals. We identi-
fied 253 differentially expressed genes in MX2-high melanocytes
(FDR < 0.01 and |log2 fold difference| >1; Supplementary Data 2),
which include many of the top correlated immune-response genes
based on pairwise comparisons of all expressed genes in the full
melanocyte set (Supplementary Data 3; Supplementary Table 10).
Significantly enriched pathways in these 253 differentially
expressed genes included those relevant to cellular immune
response as might be expected, but also included those affecting
cellular growth and cancer (Fig. 6a; Supplementary Table 11)
suggesting a possible melanocyte-specific function of MX2 not
limited to immune function. On the other hand, an examination
of immune infiltrates in melanomas from TCGA did not provide
sufficient evidence for the roles of MX2 in tumor immune sur-
veillance other than weak correlations with infiltration of a few
cell types (Supplementary Note; Supplementary Fig. 17).
Given the possibility of a melanocyte-specific function of MX2,
we hypothesized that melanocyte-specific MX2 expression might
have roles in early events of melanoma formation. To test this
hypothesis, we first asked if MX2 affects growth of primary
melanocytes and melanoma cells in a single culture system. Cell
growth assays using the xCELLigence system demonstrated
that inducible lentiviral expression of MX2 (2–10-fold induction
at 72 h; Supplementary Fig. 18a, b) resulted in slightly decreased
growth of both melanoma cells and primary melanocytes at
100 ng/ml of doxycycline treatment, while empty vector trans-
duced cells did not show any difference (Fig. 6b, c). To begin to
understand what genes and pathways might be affected by
increased MX2 expression and could potentially underlie the
altered melanoma cells/melanocytes growth, we performed RNA-
seq analyses on melanocytes over-expressing MX2 (2–10-fold
induction at 72 h; Supplementary Fig. 18a, c). Differentially
expressed genes in MX2-overexpressing melanocytes compared
to controls (158 genes, FDR < 10%; melanocytes from 3
individuals, 3 biological replicates each; Supplementary Data 4)
displayed enrichment of pathways relevant to immune response,
as well as those involving second messenger mediated kinase
signaling and cellular growth, among others (Supplementary
Table 12; Fig. 6d). We subsequently examined pathways enriched
at a shorter time point after MX2 induction (6 h, melanocytes
from one individual, 3 biological replicates) and observed
consistent results highlighting intracellular second messenger
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signaling, cancer, cell growth, neurotransmitters, cardiovascular
signaling, in addition to cellular immune response (Supplemen-
tary Note; Supplementary Data 5 and 6; Supplementary Tables 13
and 14). Since these data did not provide strong support for a
specific mechanistic hypothesis linking the effect of increased
MX2 on reduced melanocyte growth in single cultures to its
association with melanoma risk, we speculated that the effect of
MX2 on melanocyte growth might change depending on cellular
context and microenvironment.
To test this idea and establish a melanocyte-specific role for
MX2 expression in the development or progression of melanoma,
we examined transgenic expression of human MX2 in a zebrafish
melanoma model, in conjunction with the most recurrent somatic
driver event of melanoma, BRAFV600E. Using the previously
developed miniCoopR transgene system43, we over-expressed
human MX2 exclusively in the melanocytic-lineage using an
MITF promoter in the background of BRAFV600E and p53−/−.
The results demonstrated that zebrafish with transgenic human
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MX2 expression presented an accelerated melanoma formation
(46% of fish developed melanoma by 19 weeks; n= 184)
compared to those with GFP controls (33% of fish by 19 weeks;
n= 194) in this genetic background (P= 0.003; log-rank test;
Fig. 6e, f). While we did not see significant difference in tumor
count and pigmentation between the two groups, we observed
larger tumor size in the MX2 group compared to GFP control
group at median onset (P= 0.028; chi-square test), which is
consistent with accelerated tumor formation demonstrated
through survival analysis (Supplementary Fig. 19). We further
performed histopathology analyses of zebrafish melanomas and
did not observe gross difference in tumor morphology and
invasion between MX2 and GFP groups (Supplementary
Fig. 20a–d). Immunohistochemistry for phospho-Histone H3
also did not display a significant difference in cell proliferation
between two groups (P= 0.47, two-tailed t-test, n= 5; Supple-
mentary Fig. 20e–g). Together these data are consistent withMX2
expression contributing to an increased melanoma risk, however
consistent with in vitro data, likely through a mechanism other
than increased cell proliferation.
Discussion
In this study, we adopted an integrative approach combining
MPRA with cell-type specific epigenomic and eQTL data to
efficiently nominate functional variants and susceptibility genes
from 20 known melanoma GWAS loci. We demonstrate that
MPRA is a high-throughput variant prioritization tool com-
plementing statistical fine-mapping. While Bayesian fine-
mapping methods could nominate a small number of credible
causal variants for functional testing, these methods are none-
theless limited by their dependence on imputability, imputation
quality, population LD reference, causal assumptions, and choice
of functional annotation datasets44,45. Further, variants that are
tightly linked by LD are often still difficult to distinguish based
solely on the genetic data and require individual functional
testing. To this end, MPRA provides an agnostic approach to
quickly screen a large number of variants linked by LD without
relying on assumptions about LD structure or number of causals.
By applying a conservative cutoff, we identified 39 variants dis-
playing allelic transcriptional activity from 14 melanoma GWAS
loci and showed that they are more likely to change transcription
factor binding preference and more likely to be causal compared
to the rest of the tested variants. Starting from an average of 52
high-LD melanoma-associated variants per locus that overlap
active chromatin regions, MPRA narrowed the candidate variants
down to an average of 2.78 per locus. These results highlight the
utility of our approach in complementing statistical fine-mapping
and breaking up LD structure using a functional assay. To further
prioritize variants functioning through cis-regulation of local gene
expression, we integrated the 39 MPRA significant variants with
melanocyte eQTL data which best represents the cell type of
origin for melanoma. By choosing the variants displaying the
same allelic directions as those from eQTL, we nominated a short
list of candidate genes and variants from four loci. In particular,
from the locus on chromosome band 21q22.3, 5 of 22 total tested
variants are in near perfect LD (r2 > 0.99) with the GWAS lead
SNP (rs408825), including the lead SNP from the original study
identifying this locus (rs45430)9 (Supplementary Table 8). While
both Bayesian fine-mapping using PAINTOR in this study and
eQTL colocalization using eCAVIAR from our previous study24
assigned higher probability scores for some of these perfect LD
SNPs as causal variants for melanoma risk and/or eQTL, MPRA
results for this set of 22 SNPs determined rs398206 (r2= 0.94
with the lead SNP) as the most significant functional variant.
Integrating this result with melanocyte eQTL nominated MX2 as
the best candidate susceptibility gene, and we performed thor-
ough functional characterization of this locus including generat-
ing an animal model as a proof of principle.
In addition, our integrative approach efficiently identified the
most plausible susceptibility genes and functional variants from
three other melanoma GWAS loci. For the melanoma locus on
chromosome band 22q13.1, increased MAFF levels were corre-
lated with risk. MAFF is a small Maf protein regulated by EGF
signaling46 and plays a role in the oxidative stress response47,
which is relevant to melanomagenesis, given the vulnerability of
melanocytes to oxidative stress attributable to melanin produc-
tion48. For the locus on chromosome band 1q21.3 and 2q33-q34,
lower CTSS and CASP8 levels were correlated with the risk,
respectively. CTSS is a member of cathepsin proteases, initially
known as lysosomal enzymes49. Increased expression of CTSS is
correlated with poor prognosis in the context of some cancers
(breast and colorectal cancer) but also correlated with better
outcome in others (lung cancer). CASP8 is mainly known for its
function in apoptosis50, and GWAS also implicated the CASP8
locus for breast cancer51 and basal cell carcinoma52. Our results
provide strong support for these three genes and warrant further
in-depth characterization.
Our approach also successfully identified a small number of
candidate functional variants (median 1 variant per locus) in nine
Fig. 6 MX2 accelerates melanoma formation. a Ingenuity Pathway Analysis of differentially expressed genes from MX2-high vs. MX2-low melanocytes
from 106 individuals. 252 differentially expressed genes (FDR < 1% and >2-fold change) between MX2-high and MX2-low melanocytes (top and bottom
quantile based onMX2 levels; n= 28 each) from 106 individuals were used as input for the analysis. Enrichment P-values are based on a two-sided Fisher’s
exact test with no multiple-testing correction applied. (B-C) Cell growth and movement of human primary melanocytes C23 (b) or melanoma cell line
UACC2545 (c) infected with an inducible lentiviral construct of MX2 cDNA or Empty pINDUCER20 vector were measured on xCELLigence system. Cell
Index values were normalized relative to those at the time of doxycycline addition (dotted vertical line: Dox). The amount of doxycycline (dox) is shown in
ng/ml and color-coded. Mean Normalized Cell Index (colored dots) and SD (gray vertical lines) are plotted (n= 3). A representative set of three biological
replicates is shown. d Ingenuity Pathway Analysis of differentially expressed genes from RNA sequencing of MX2 overexpressed vs. control melanocytes
from 3 individuals. 158 differentially expressed genes (FDR < 10%) between MX2-overexpressing (100 ng/ml doxycycline) vs. control (no doxycycline)
melanocytes using 3 biological replicates for 3 individuals were used as input for the analysis. Significantly enriched canonical pathways (P < 0.05 and |Z-
score| >1) are color-coded for the direction of effect relative to MX2-high melanocytes (a) or MX2-overexpressing melanocytes (d). Enrichment P-values
are based on a two-sided Fisher’s exact test with no multiple-testing correction applied. A weaker to stronger shade of each color represent the relative
magnitude of Z-scores: Positive Z-score between 1 and 2.646 and negative Z-score between −1 and −3.464 (a) or positive between 1 and 1.134 and
negative between −1.342 and −2.236 (d), where lightest red is closer to 1 and lightest blue is closer to −1. (e) Representative pictures of adult fish from
GFP or MX2 group. Pictures were taken at week 10 post-injection. f Melanoma-free survival curves of a zebrafish melanoma model43 (Tg(mitfa:
BRAFV600E), p53−/−, mitfa−/−). The fish were injected at the one cell stage with either miniCoopR mitfa:MX2 or miniCoopR mitfa:EGFP and monitored
weekly for melanoma formation. The percentage of melanoma-free fish was combined from three independent experiments and plotted. Log-rank test was
used. Source data are provided as a Source Data file.
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melanoma loci not currently supported by cell-type specific
melanocyte eQTLs (Supplementary Table 6). These variants may
represent plausible functional candidates for loci where we are
underpowered to detect melanocyte cis-eQTLs from only 106
cultures. Alternatively, as our eQTL dataset is based on gene
expression patterns captured in cultured primary melanocytes, it
is possible that these variants may function within specific cellular
contexts not captured in this eQTL dataset. Given that our
MPRA assay was conducted in melanoma cells, it may be possible
that such variants, for example, may only be functioning in the
context of oncogenic signaling (e.g., oncogenic BRAF),
tumor suppressor loss (e.g., CDKN2A), or immortalizing events
(e.g., mutation of the TERT promoter). Future evaluation of
these variants in the context of additional genome-scale
datasets, including cell-type specific chromatin interaction data,
as well as chromatin features of different cellular contexts, may
strengthen or clarify evidence for functionality of leads for
these loci.
Through molecular interrogation, we demonstrated that a
melanoma-associated intronic variant, rs398206, contributes to
allelic expression of MX2 via modifying an enhancer element
recruiting the transcription factor, YY1. Our multi-QTL analyses
of primary melanocytes further supported a transcriptional
mechanism, while ruling out an alternative mechanism through
splicing. While our data demonstrated the YY1 transcription
factor plays a major role in MX2 regulation via the functional
SNP, it is also possible that other trans-acting factors, perhaps
among other proteins identified through mass-spec with less
pronounced allelic difference (e.g., KLF9, ZBTB7A, PAX3),
could also play a role in the observed allelic transcriptional
regulation.
Our zebrafish model provided further support for MX2 as a
melanoma susceptibility gene accelerating melanoma formation
when expressed in the cells of melanocytic-lineage. MX2 has been
mainly known as an effector of innate-immunity, conferring
restriction to HIV-1 infection40,41, and its roles in melanoma-
genesis have not been studied well. Our findings suggest a role of
MX2 in promoting melanoma formation when exclusively
expressed in cells of melanocytic-lineage, in the presence of
BRAFV600E, a frequent somatic driver mutation. Unlike the
relatively high level of MX2 overexpression in the zebrafish
model, increased melanoma risk and MX2 levels associated with
this common functional variant (rs398206 risk allele frequency=
0.61, EUR) in human populations are rather modest, which is
nearly always the case for cancer-associated common variants. It
is possible that the effect of increased MX2 levels have roles only
in specific contexts during the process of melanoma development.
Our single cell-type growth assays for MX2 also show growth
effects for MX2 in melanocytic-lineage in the absence of neigh-
boring cell types from the skin, albeit in the opposite direction. A
recent study also reported that MX2 over-expression resulted in
decreased growth in primary melanocytes and melanoma cells,
while the effect could be the opposite in a subset of melanoma
cells53. Our zebrafish tumor proliferation assay also suggested
that accelerated melanoma formation by MX2 might not be due
to increased proliferation per se. Given this apparent complexity,
we speculate that MX2 function in the growth of cells of mela-
nocytic lineage might depend on cellular context (e.g., somatic
driver events) and or interaction with microenvironment (e.g.,
immune cells). Further studies will be required to tease out the
discrepancy between single cell-type assay and zebrafish
model, as well as the molecular mechanisms of how MX2 con-
tributes to melanoma promotion. Nevertheless, our findings
established MX2 as a gene displaying pleiotropic roles in mela-
noma susceptibility and immune response, building on to the
established roles of telomere biology (TERT, Chr5p15.33)19 and
oncogene-induced senescence (PARP1, Chr1q42.1)18 in genetic
susceptibility to melanoma in the general population.
Methods
Melanoma GWAS fine-mapping. Fine-mapping of the 20 genome-wide sig-
nificant loci from the meta-analysis reported by Law and colleagues1 was con-
ducted following a very similar approach to that of Barrett et al.54. Using the results
from Law et al.1 a window was defined as 1Mb on either side of the most sig-
nificant variant at each locus. The only exception to this was the region that
included the ASIP gene (20q11.2-q12), where a 6Mb region was instead defined, as
this region demonstrated a long-range linkage disequilibrium. Melanoma case/
control status was regressed on each genotyped and imputed variant in turn across
these regions, with the first four principal components as covariates to account for
stratification on 12,419 cases and 14,242 controls from the meta-analysis (only the
Harvard GWAS samples and the endometriosis controls from the Q-MEGA_610k
study were unavailable). Each region was further narrowed down to the interval
covering 500 kb on either side of the most extreme SNPs with p-value <10−6 in the
initial single SNP analysis and any variants with an imputation INFO score <0.5
(for variants with MAF >= 0.03) or INFO score <0.8 (for variants with MAF <
0.03) was removed. A Bayesian-inspired penalized maximum likelihood approach
implemented in HyperLasso25 was applied to these regions. 100 iterations of
HyperLasso were then conducted, using all variants in each region and a Normal
Exponential Gamma prior distribution for SNP effects with a shape parameter
1.055,56 and scale parameter such that type 1 error is 10−4. Both the study (as a
categorical variable) and the first four components were included as covariates.
Because of the stochastic nature of the order in which variables are tested for
inclusion, this produced a number of potential models, including some that can be
considered to ‘correspond’ to one another, because they differ only by substituting
genetic variants that are in very strong LD (r2 > 0.9). By dropping equivalent
models, a reduced set of models was produced and was then further reduced by
dropping any model whose likelihood was inferior to that of the best model by a
factor >= 10. For each remaining model, a logistic regression was conducted using
the SNPs in the model to generate adjusted odds ratios. For SNPs retained in any of
the models, LD blocks were defined (based on both the HyperLasso results and
strength of LD) and the most significant SNP (in a multivariable analysis) from
each block was selected. rs36115365 in the region near TERT gene (5p15.33) was
not identified in the fine-mapping but included for variant selection as it was
identified previously based on functional evidence19. Subsequent analysis showed
that the risk-associated alleles at rs36115365 and at rs2447853 (the most significant
SNP in the region at the time) are in negative LD and when adjusted for the latter
SNP, rs36115365 has a P-value of 10−4 (Supplementary Table 1). Similarly, for the
locus on chromosome band 2p22.2, the optimal model was a 2-SNP, but the
secondary signal at rs163094 displayed low INFO scores in some studies rendering
imputation less optimal and hence was not used for variant selection. Instead, the
best SNP identified by 1-SNP model (rs1056837; a missense variant of CYP1B1)
was included as an alternative (Supplementary Table 1). Since the effect of the
region around MC1R gene (16q24.3) on melanoma risk is mainly explained by
several well-established coding variants12, we did not include this region in our
fine-mapping data.
MPRA variant selection. Among 20 genome-wide significant loci from the mel-
anoma meta-analyses by Law and colleagues1, we prioritized 16 loci where
potential cis-regulatory mechanism could be applied. We excluded the other 4 loci
containing genes that are implicated in melanoma-associated pigmentation phe-
notypes (SLC45A2, TYR, MC1R, and ASIP loci), as for many of these genes, coding
variants were shown to alter the protein functions. To select high-LD proxy var-
iants for 16 melanoma GWAS loci (Law et al., 20151), we used the following
criteria:
1. Primary lead SNPs were taken from Law et al.1 meta-analysis paper and
supplemented by those from additional HyperLasso analysis when there are
alternative best SNPs available.
2. For 8 loci, HyperLasso analysis nominated independent multiple secondary
signals and these lead SNPs were also added.
3. SNPs of r2 > 0.4 with the primary or secondary lead SNPs using 1000
Genomes phase3 EUR or CEU populations were selected as high-LD
variants (n= 2748).
To prioritize high-LD variants overlapping melanocyte/melanoma open
chromatin regions and/or active promoter/enhancer histone marks, we used one or
more of the following criteria:
1. Variant is located within a human melanocyte DHS peak from one or more
individuals of three available through ENCODE and Epigenome Roadmap
database.
2. Variant is located within a human melanocyte H3K27Ac ChIP-Seq peak
from one or more individuals and a H3K4Me1 ChIP-Seq peak from one or
more individuals of two and three available through Epigenome Roadmap
database, respectively.
3. Variant is located within a human melanocyte H3K27Ac ChIP-Seq peak
from one or more individuals and a H3K4Me3 ChIP-Seq peak from one or
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more individuals of two and three available through Epigenome Roadmap
database, respectively.
4. Variant is located within a human melanoma short-term culture FAIRE-Seq
peak from one or more individuals of 11 available from Verfaillie et al.26.
Based on the above criteria, 832 melanoma GWAS variants were selected to be
tested by MPRA. We also included 8 additional variants from Chr1q21.3 that were
of r2 > 0.8 with the lead SNP but did not overlap with any functional signature
listed above and assigned them as negative controls. Of 832 variants, 306, as well as
8 negative controls were repeated in two libraries to ensure cross-library
consistency (see MPRA oligo library design). These 306 variants are also r2 > 0.6
with their lead SNPs and supported by both open chromatin and histone mark
annotation from melanocyte or melanoma data. A complete list of variants tested
are listed in Supplementary Data 1.
MPRA oligo library design. Oligo libraries were designed mainly following the
guidelines from published works21,27 with some modifications. Two libraries con-
taining 32,580 (library 1) and 36,660 (library 2) unique sequence of 200-mer oligos
(total of 50,400 unique sequences across two libraries with 18,840 repeated in both)
were synthesized by Agilent Technologies (Santa Clara, CA). Composition of each
library by GWAS locus and repeated variants are listed in Supplementary Data 1
and Supplementary Table 3. For each variant, 145 bases encompassing the variant
with either risk or protective allele in both forward and reverse directions were
synthesized together with 10 different 10 base random barcode sequences. These
two parts of sequences were separated by recognition sequences for restriction
enzymes KpnI (GGTACC) and XbaI (TCTAGA), and flanked by binding sequences
for PCR primers (200 bases oligo sequences: 5’-ACTGGCCGCTTCACTG-145
bases-GGTACCTCTAGA-10 bases tag-AGATCGGAAGAGCGTCG-3’). For each
variant, a scrambled sequence (core 21 bases encompassing the SNP with the
reference allele were shuffled) was also tested in forward and reverse directions in
the same manner. This is equivalent to a total of 60 unique sequences designed per
variant. When there are additional SNPs other than the test SNP that fall in the 145
bp region, major allele in EUR population was used. For indels, 145 bases length was
set based on insertion allele and the deletion allele was left shorter than 145 bases.
Random 10 base tag sequences were generated once so that each library has up to
36,660 unique tag sequences (the same 36,660 tag sequences were used for each
library). For the 10 base tag sequence and scrambled 21 base core sequence, only
homopolymers of <4 bases were used and the enzyme recognition sites for KpnI,
XbaI, and SfiI were avoided. A complete list of oligo sequences can be found in
Supplementary Data 7.
MPRA library construction and sequencing. MPRA library construction and
sequencing was performed following published protocols with some modifica-
tions21,27. For library cloning, ten femtomole each of gel-purified (10% TBE-Urea
polyacrylamide gel) oligo libraries was amplified by emulsion PCR using Herculase
II fusion polymerase (Agilent) and 2 µM of primers providing SfiI enzyme sites
(Supplementary Table 15), following the instructions of the Micellula DNA
Emulsion & Purification Kit (EURx/CHIMERx, Milwaukee, WI). Amplified oligos
were quantified using KAPA qPCR assay and verified by DNA sequencing on Ion
PGM. Amplicon libraries were prepared using 30 ng of oligos from emulsion PCR
using Ion Plus Fragment Library Kit (Thermo Fisher, Waltham, MA) and were
sequenced on Ion PGM for an average 203 bp and 175 bp read length at 6.7 million
and 5.6 million reads per sample for library 1 and library 2, respectively. To verify
oligo library design, 21 bp sequences within oligos including variant site and +/−
10 bp were used to map to each sequencing read. Linux command fgrep was used
and only 100% sequence match was kept. We then counted the total read depth for
each variant represented by the matched sequences, and then calculated the pro-
portion of variant sequences that were verified. For both library 1 and library 2,
more than 97% of unique sequences representing the variants in the library were
detected with at least 10 sequencing reads. In addition, we found similar proportion
and read depth for sequences representing both forward and reverse directions in
both libraries. If we use the actual tag sequences as a bait, 82% of tags could be
verified, with a caveat that some tags were amplified but not detected because of
relatively poor sequencing quality in this position of the amplicon. Sequence-
verified oligo libraries were first cloned into pMPRA1 vector (Addgene, Water-
town, MA) using SfiI site by electroporation into 10 times higher number of
bacterial cells than the number of unique sequences in the oligo library. Cloned
pMPRA1 was further digested on KpnI and XbaI sites between 145 bp test
sequence and 10 bp barcode sequence, where luc2 ORF with or without a minimal
promoter was ligated from pMPRAdonor2 and pMPRAdonor1 (Addgene),
respectively. The ligation product was transformed by electroporation into 10 times
higher number of bacterial cells in the same manner. Cloned final library for
transfection was verified on the gel as a single band after KpnI digestion.
Each library was transfected at least four times (two transfections for each
promoter type) into HEK293FT or UACC903 melanoma cells aiming >100 times
higher number of transfected cells than the library complexity. The number of
transfected cells were estimated using transfection efficiency measured by a
separate GFP transfection and visualization. A summary of transfections is listed in
Supplementary Table 4. Cells were transfected using Lipofectamine 3000 and
harvested at 24 h after transfection for RNA isolation. Total RNA was isolated
using Qiagen RNeasy kit (Qiagen, Hilden, Germany), and mRNA was subsequently
isolated using PolyA purist MAG kit (Thermo Fisher). cDNA was then synthesized
using Superscript III, from which only short sequences encompassing 10 bp unique
barcodes were amplified using Q5 high-fidelity polymerase (NEB, Ipswich, MA)
and primers introducing Illumina TruSeq adapter sequences (Supplementary
Table 15). Tag sequence libraries were also prepared using input DNA in the same
way. Each tag sequence library was sequenced on a single lane of HiSeq2500 (125
bp paired end read).
MPRA data analyses. Using FASTQ files from input DNA or RNA transcript
sequencing, we counted the number of reads (Illumina read 1) completely
matching 10 bp barcode sequences (tag counts) and the same downstream
sequence context (TCTAGAATTATTACACGGCG) including an XbaI recognition
site and the 3’ of the luc2 gene. For each transfection (equivalent to one sequencing
run), Tag counts Per Million sequencing reads (TPM) values were calculated by
dividing each tag count by the total number of sequence-matching tag counts
divided by a million. TPM ratio was then taken as RNA TPM over input DNA
TPM and log2 converted.
From each input DNA library at least 92.1% of barcode sequences were
detected, and >89.3% were covered at 10 reads or higher. From RNA samples
87.4–93.3% of barcode sequences were detected, and 84.8–90.8% were covered at
10 reads or higher (Supplementary Table 4). Barcodes showing 10 tag counts or
lower were excluded from the further analyses. Median tag counts for the barcodes
that were included in the analyses were 48,973–49,903 for DNA input and
46,471–49,758 for RNA output. Reproducibility between transfections were
assessed by Pearson correlation of log2-transformed TPM ratio of each barcode
between replicates of transfection. We observed correlation coefficient of 0.944 or
higher for each library transfected to HEK293FT cells and 0.935 or higher for
UACC903 cells (median Pearson r= 0.984; Supplementary Fig. 3). Correlation test
was also performed between repeated sequences across libraries. We observed
correlation coefficient of 0.821 or higher for HEK293FT cells (Supplementary
Fig. 4) and 0.815 or higher for UACC903 cells (Supplementary Fig. 5; median
Pearson r= 0.854). To avoid low input DNA counts driving variations in RNA/
DNA TPM ratios, we removed tags with <6 TPM counts from further analyses. The
remaining tags account for 77.47% of all the detected tags (Supplementary Fig. 6).
We analyzed the normalized MPRA measurement (log2 transformed TPM
ratio) using a standard linear regression model. We used the Wald test to test the
impact of allele on MPRA level, after adjusting the effect of Strand (forward or
reverse direction) as a binary covariate, the effect of Transfection as a categorical
covariate with 18 levels (accounting for different promoter status and cell types, as
well as cross-transfection variations). To account for the potential
heteroskedasticity in the measurement error, we used the robust sandwich type
variance estimate in the Wald test as recommended by Long and Ervin57, and used
the R package Sandwich to conduct the analysis. To assess overall transcriptional
activity of the 145 bp DNA element including the variant, we used variant-specific
scrambled sequences as a null. Log2 transformed TPM ratios of scrambled
sequences were regressed against those of either reference or alternative allele while
using the same covariates (Strand and Transfection). Log2 TPM ratio for each tag
in each transfection was considered as an experimental replicate for regression. The
same set of analyses was done only using data from UACC903 melanoma cells and
further dropping data for repeated variants from one of two libraries (library 1) to
allow subsequent enrichment analyses. Variants showing FDR < 0.01 for both
allelic difference and departure from null (for either allele) in both UACC903 only
and combined set were called as significant MPRA variants. Complete processed
MPRA data can be found in Supplementary Data 7.
Integration of MPRA variants with melanocyte eQTL variants. Significant
eQTL genes were defined as candidate genes significantly identified by eCAVIAR
(CLPP > 0.01) or TWAS (P-value < 0.05/number of genes tested) in melanocytes24.
Among all 832 variants, variants were selected if they display genome-wide sig-
nificant melanocyte eQTL P-values (nominal P-value < gene-level genome-wide
threshold as defined in Zhang et al.24) for one of the significant eQTL genes. Six
genes (ARNT, CTSS, PARP1, CASP8, MX2, and MAFF) from five loci had sig-
nificant eQTL SNPs included in MPRA, and the final MPRA-significant variants
overlapped eQTL SNPs in four loci, where a subset of SNPs also displayed the same
allelic directions between MPRA and melanocyte eQTL for four genes (CTSS,
CASP8, MX2, and MAFF; Supplementary Table 6).
Motif analysis. Prediction of variant effects on transcription factor binding sites
was performed using the motifbreakR package28 and a comprehensive collection of
human transcription factor binding sites models (HOCOMOCO)58. We selected
the information content algorithm and used a threshold of 0.001 as the maximum
P-value for a transcription binding site match in motifbreakR. Log2 fold change
between alternative allele score and reference allele score were used to predict the
transcription factor motif effect for each variant.
Statistical fine-mapping using PAINTOR. PAINTOR 3.0 (http://bogdan.
bioinformatics.ucla.edu/software/paintor) was used to estimate the posterior
probability of any SNP within a melanoma locus to be causal. We used default
parameters in PAINTOR (window size of 100Kb, max causals 2) and filtered out all
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the SNPs with P-value >0.5 for computational efficiency. The pairwise LD between
all SNPs in each window was computed using the 1000 Genomes EUR data.
Functional annotations were provided as part of PAINTOR software which was
complimented with a melanocyte specific gene set annotation24. In order to
determine which annotations are relevant to the phenotype being considered, we
ran PAINTOR on each annotation independently and then selected 4 annotations
specific to primary melanocytes with high sum of log Bayes factors for the final
model to compute trait-specific posterior probabilities for causality. These 4
annotations include melanocyte-specific expressed genes from our melanocyte
dataset24, melanocyte enhancers, transcribed regions, and a histone mark
(H3T11ph) from ENCODE and Roadmap. Aside from the variants not meeting
our analysis parameters, 462 out of 832 MPRA-tested variants were assigned a
posterior probability by PAINTOR and were used for enrichment analyses.
Melanocyte eQTL, sQTL, and meQTL for the MX2 locus. Primary melanocyte
eQTL data was obtained from our previous study24, where 106 individuals mainly
of European decent were analyzed. For the marginal eQTL analysis of the genes
located in the TAD including rs398206, 21 genes were selected based on expression
thresholds of >0.5 by RSEM quantification (RNA-Seq by Expectation Maximiza-
tion59) and ≥6 reads in at least 10 samples. Using FastQTL60, nominal P-value was
generated between each gene and all the SNPs +/−2Mb of rs398206 to test the
alternative hypothesis that the slope of a linear regression model between the
genotypes and expression levels deviates from 0. The same set of covariates as that
used for the eQTL analyses was applied (three top genotype PCs and 10 top PEER
factors). A Bonferroni-corrected cutoff of P < 0.0024 for 21 genes was then applied
to select the genes showing marginal eQTL with rs398206. For sQTL, and meQTL,
we performed similar QTL analyses as our previous eQTL study using the same
genotype data, population structure covariates, and statistical approaches. We
replaced normalized gene expression levels with normalized splice junction events
(sQTL), and normalized methylation values (meQTL). We also re-calculated the
top 15 PEER factors according to these phenotype values. For sQTL analysis,
STAR61 was used to map the RNA-Seq reads onto the genome (hg19) and then
LeafCutter30 was applied to quantify the splice junctions following the procedures
described by the authors (http://davidaknowles.github.io/leafcutter/articles/sQTL.
html). For meQTL analysis, we performed genome-wide DNA methylation pro-
filing on Illumina Infinium Human Methylation 450 K BeadChip. Methylation
levels of all 106 primary melanocyte samples was measured according to the
manufacturer’s instruction at Cancer Genomics Research Laboratory at NCI.
Measurement of raw methylation densities and quality control were conducted
using the RnBeads pipeline62 and the minfi package63 (http://bioconductor.org/
packages/minfi/). In total, we retained 635,022 probes for the downstream meQTL
analysis. No batch effects were identified and there were no plating issues. To
obtain the final methylation levels (beta value) for meQTL anlaysis, normalization
was performed using the preprocessFunnorm algorithm implemented in minfi R
package63.
MX2 isoform analysis. Taqman assays targeting unique junctions of MX2 tran-
script isoforms were obtained from Thermo Fisher (Waltham, MA, full-length
transcript: Hs01550809_m1 and AP323EZ; ENST00000543692: APYMKKU;
ENST00000418103: AP2W9U3). Custom assay design was based on Ensembl75
GRCh37 annotation. RNA was isolated from primary cultures of melanocyte from
106 individuals mainly of European decent24, and cDNA was synthesized using
iScript Advanced cDNA Synthesis Kit (Bio-Rad). Taqman assays were performed
in triplicates (technical replicates) to be averaged to single data points and nor-
malized to TBP levels. TBP was selected among 16 conventional human control
genes as being one of the least variable genes in melanocyte dataset based on RNA-
seq data.
Cell culture. Melanoma cell lines (UACC903, UACC647, UACC2331, UACC502,
UACC2545, and UACC612) were grown in the medium containing RPMI1640,
10% FBS, 20 mM HEPES, and Amphotericin B/penicillin/streptomycin. All cell
lines were tested negative for mycoplasma contamination.
Luciferase assays. For each tested SNP, the exact same 145 bp sequence
encompassing rs398206 as tested in MPRA was amplified from genomic DNA of
HapMap CEU panel samples carrying either risk or protective allele. Primers were
designed to carry 15 base 5’ overhangs recognizing either side of pGL4.23 vector
after KpnI single cut in both forward and reverse direction to facilitate recombi-
nation (Supplementary Table 15). Amplified fragments containing 145 bp sequence
were then cloned into pGL4.23 vector using In-Fusion HD Cloning kit (Clontech).
The resulting constructs were co-transfected with renilla luciferase into melanoma
cell lines (UACC903 and UACC502) using Lipofetamine 2000 reagent following
the manufacturer’s instructions (Thermo Fisher) in 24-well format. Cells were
harvested at 24 h after transfection for luciferase activity assays. All the experiments
were performed in at least three biological replicates in sets of 6 replicates.
EMSA and super-shifts. Forward and reverse strand of 21-mer DNA oligos
encompassing rs398206 were synthesized with 5’ biotin labeling (Life Technologies;
Supplementary Table 15) and were annealed to make double stranded probes.
Nuclear extracts were prepared from actively growing melanoma cells
(UACC2331) using NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Thermo Scientific). Probes were bound to 2 µg nuclear extracts pre-incubated with
1 µg poly d(I-C) (Roche, Basel, Switzerland) or 100–750 ng YY1 full-length
recombinant protein (31332, Active Motif, Carlsbad, CA) in binding buffer con-
taining 10 mM Tris (pH 7.5), 50 mM KCl, 1 mM DTT, and 10 mM MgCl2 at 4 °C
for 30 min. For competition assay, unlabeled competitor oligos were added to the
reaction mixture 5 min prior to the addition of probes. Completed reactions were
run on 5% or 4–20% native acrylamide gel and transferred blots were developed
using LightShift Chemiluminescent EMSA kit (Thermo Scientific) and imaged on
Chemidoc Touch (Bio-Rad, Hercules, CA). For antibody-supershifts, 0.6–1.2 µg of
antibody against YY1 (sc-1703×, Santa Cruz, Dallas, TX) or rabbit normal IgG (sc-
2027, Santa Cruz) were bound to nuclear extract prior to poly d(I-C) (Roche)
incubation at 4 °C for 1 h.
Chromatin immunoprecipitation and genotyping. Melanoma cells (UACC903,
UACC647, and UACC612) were fixed with 1% formaldehyde when ~85% con-
fluent, following the instructions of Active Motif ChIP-IT high sensitivity kit. 7.5 ×
106 cells were then homogenized and sheared by sonication using a Bioruptor
(Diagenode) at high setting for 15 min, with 30 s on and 30 s off cycles. Sheared
chromatin from 2 × 106 cells were used for each immunoprecipitation with anti-
bodies against YY1 (sc-1703×, Santa Cruz), or normal rabbit IgG (sc-2027; Santa
Cruz) following the manufacturer’s instructions. Purified pulled-down DNA or
input DNA was assayed by SYBR Green qPCR for enrichment of target sites using
primers listed in Supplementary Table 15. A positive control primer set for YY1
binding was designed targeting a known YY1 binding site near RAF1 gene pro-
moter as reported by Weintraub and colleagues39. Relative quantity of each sample
was driven from standard curve of each primer set and normalized to 1/100 input
DNA. For genotyping rs398206, input DNA or genomic DNA from each cell line,
and pulled down DNA from UACC647 cell line (heterozygous for rs398206) was
used as template DNA for Taqman genotyping assay (Assay ID: C_2265405_20).
All experiments were performed in at least three biological replicates in sets of
triplicates.
Mass spectrometry. Nuclear lysates for mass spectrometry analysis were collected
from UACC903 cells grown in RPMI 1640 media (Gibco) supplemented with 10%
FBS, 20 mM HEPES (pH 7.9), 100 U/ml penicillin and 100 μg/ml streptomycin
(Gibco)64. 21 bp oligonucleotide probes encompassing rs398206 were ordered via
custom synthesis from Integrated DNA Technologies with 5’-biotinylation of the
forward strand (Supplementary Table 15). Forward and reverse DNA oligos were
annealed using a 1.5X molar excess of the reverse strand. DNA pulldowns and on-
bead digestion were performed on a 96-well filterplate system as described pre-
viously65. In short, 500 pmol of annealed DNA oligos were immobilized on 10 μl
(20 μl slurry) Streptavidin-Sepharose beads (GE Healthcare, Chicago, IL) for each
pulldown. Immobilized DNA oligos were incubated with 500 μg of UACC903
nuclear extract and 10 μg of non-specific competitor DNA (5 μg polydAdT, 5 μg
polydIdC). After washing away unbound proteins, beads were resuspended in
elution buffer (2 M Urea, 100 mM TRIS (pH 8), 10 mM DTT), alkylated with
55 mM iodoacetamide, and on-bead digested with 0.25 μg trypsin. After desalting
using Stage tips, peptides were labeled by stable isotope dimethyl labeling, as
described previously65. Each pulldown was performed in duplicate and label
swapping was performed between replicates to eliminate labeling bias. Matching
light and heavy peptides were combined and loaded onto a 30 cm column (heated
at 40 °C) packed in-house with 1.8 um Reprosil-Pur C18-AQ (Dr. Maisch, GmbH).
The peptides were eluted from the column using a gradient from 9 to 32% Buffer B
(80% acetonitrile, 0.1% formic acid) in 114 min at a flow rate of 250 nL/min using
an Easy-nLC 1000 (Thermo Fisher). Samples were sprayed directly into a Thermo
Fisher Orbitrap Fusion Tribrid mass spectrometer. Target values for full MS were
set to 3e5 AGC target and a maximum injection time of 50 ms. Full MS were
recorded at a resolution of 120,000 at a scan range of 400–1500 m/z. The most
intense precursors with a charge state between 2 and 7 were selected for MS/MS
analysis, with an intensity threshold of 10000 and dynamic exclusion for 60 s.
Target values for MS/MS were set at 2e4 AGC target with a maximum injection
time of 35 ms. Ion trap scan rate was set to ‘rapid’ with an isolation width of 1.6
m/z and collision energy of 35%. Scans were collected in data-dependent top-speed
mode in cycles of 3 s. Thermo RAW files were analyzed with MaxQuant 1.6.0.1 by
searching against the UniProt curated human proteome (released June 2017) with
standard settings66. Protein ratios were normalized by median ratio shifting and
used for outlier calling. An outlier cutoff of 1.5 inter-quartile ranges in two out of
two biological replicates was used.
siRNA knockdown of YY1. siRNA knockdown of YY1 was performed in the
UACC647 melanoma cell line using ON-TARGETplus YY1 siRNAs (J-011796-08,
J-011796-09, J-011796-10, and J-011796-11; Dharmacon). Non-targeting siRNA
and siRNA targeting GAPDH were used for negative and positive control,
respectively. Six picomole of siRNA was transfected into 5 × 104 cells using Lipo-
fectamine RNAiMax (Thermo Fisher) following the reverse transfection procedure
in 24-well format. Cells were harvested at 72 h after transfection for RNA isolation.
The experiments were performed in 4 biological replicates in sets of 6 replicates.
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Total RNA was isolated using RNeasy kit (Qiagen) and cDNA was generated using
iScript Advanced cDNA Synthesis Kit (Bio-Rad). MX2 levels were measured using
Taqman probe set (Assay ID: Hs01550809_m1) specifically detecting the full-
length isoform and normalized to GAPDH levels. qPCR triplicates (technical
replicates) were averaged to be considered as one data point. Cells were also
harvested for protein isolation from each biological replicate to assess knockdown
efficiency by Western blot analysis. Total cell lysates were generated with RIPA
buffer (Thermo Scientific, Pittsburgh, PA) and subjected to water bath sonication.
Samples were resolved by 4–12% Bis-Tris ready gel (Invitrogen, Carlsbad, CA)
electrophoresis. The primary antibodies used were rabbit anti-YY1 (sc-1703×,
Santa Cruz), and mouse anti-GAPDH (sc-51907, Santa Cruz). Uncropped gel
images and molecular weight marker images for western blot analysis are provided
for the corresponding figure in Source Data file.
CRISPRi of rs398206. CRISPRi was performed in UACC903 melanoma cell line
(AA genotype for rs398206) using four different gRNAs targeting the genomic region
on or near rs398206 (gRNA sequences are listed in Supplementary Table 15). Guide
RNA target sites were identified using the sgRNA Scorer 2.0 algorithm67. Non-
targeting gRNA and gRNA targeting the adeno-associated virus site 1 (AAVS1) were
used as controls. For each sgRNA, forward and reverse oligonucleotides were
annealed and cloned into vector carrying the sgRNA scaffold using the BsmBI
restriction enzyme (NEB). For CRISPRi, 400 ng of the vectors containing gRNAs,
500 ng of dCas9-KRAB-MeCP2 (Addgene: 110821) or dCAS9 (Addgene: 47316), and
100 ng of pCMV6-entry vector (carrying neomycin resistance marker) were co-
transfected into 2 × 105 cells using Lipofectamine 2000 (Thermo Fisher) following a
reverse transfection procedure scaled to 12-well format. Half the amount of DNA,
lipofectamine, and cells were used when conducting 24-well format of culture. Cells
were treated with 1mg/ml Geneticin (Gibco) 24 h after transfection. Cells were
harvested 48 h after drug selection for RNA and protein isolation. The experiments
were performed in at least 3 biological replicates in sets of 5–6 replicates. Total RNA
was isolated using RNeasy kit (Qiagen) and cDNA was generated using iScript
Advanced cDNA Synthesis Kit (Bio-Rad). MX2 levels were measured using Taqman
probe set (Assay ID: Hs01550809_m1) specifically detecting the full-length isoform
and normalized to GAPDH levels. qPCR triplicates (technical replicates) were aver-
aged to be considered as one data point. UACC903 cells tested negative for myco-
plasma. Cells were concomitantly transfected and harvested for protein isolation from
one representative set of dCAS9 vs. dCas9-KRAB-MeCP2 experiments (Supple-
mentary Fig. 15c, d) for western blotting following the same procedure described
before. Proteins were separated on NuPAGE 3–8% Tris-Acetate Protein Gels
(Thermo Fisher). The primary antibodies used were mouse anti-CAS9 (7A9–3A3,
Active Motif), and mouse anti-GAPDH (sc-51907, Santa Cruz). Uncropped gel
images and molecular weight marker images for western blot analysis are provided for
the corresponding figure in Source Data file.
MX2 allele-specific expression. Melanocyte cells were grown in Dermal Cell Basal
Medium (ATCC PCS-200-030) supplemented with Melanocyte Growth Kit (ATCC
PCS-200-041) and 1% amphotericin B/penicillin/streptomycin (120-096-711, Quality
Biological) as described before24. Total RNA was isolated using a miRNeasy Mini kit
(217004, Qiagen) further treated with CTAB-Urea following a previously described
method68 to remove excess melanin pigmentation. cDNA was synthesized from total
RNA using iScript Advanced cDNA Synthesis Kit (Bio-Rad). Genomic DNA and
cDNA were then genotyped for rs398206 using custom Taqman genotyping probe set
(ANRWEYM) recognizing both genomic DNA and cDNA (ENST00000543692) with
a 5 bp 5’ overhang on the left primer for cDNA based on Ensembl archive 75
annotation. From a total of 44 samples heterozygous for rs398206, 27 samples passing
QC (Ct values lower than 38 for both alleles in cDNA and genomic DNA) were used
to calculate A/C allelic ratio based on dRn values.
MX2 over-expression and growth assays. Melanoma cells and melanocyte
growth assays were conducted using lentiviral transduction of MX2 cDNA under
the control of tetracycline-inducible promoter using pINDUCER20 vector
(Addgene). The MX2 cDNA clone (RC206437) in the pCMV6-entry backbone was
purchased from Origene and full-length MX2 cDNA sequence was sub-cloned to
pENTR-1A vector by introducing stop codons and removing 3’ Myc-DDK tag
before being transferred to pINDUCER20 vector (adapter sequence is listed in
Supplementary Table 15). BamHI and MluI sites on pCMV6-entry vector and
BamHI and XhoI sites on pENTR-1A were used for sub-cloning. Primary human
melanocytes were obtained from Invitrogen and/or the Yale SPORE in Skin Cancer
Specimen Resource Core and grown under standard culture conditions using
Medium M254 (Invitrogen) with Human Melanocyte Growth Supplement-2
(Invitrogen). For lentivirus production, lentiviral vectors were co-transfected into
HEK293FT cells with packaging vectors psPAX2, pMD2-G, and pCAG4-RTR2.
Virus was collected two days after transfection and concentrated by Vivaspin20.
Cells were incubated with virus for 24 h, followed by drug selection (1 mg/ml
Geneticin, Gibco), before being subjected to experimental treatments and assays.
For xCELLigence assays, optimized number of cells for each cell type were seeded
to RTCA E-plate 16 and grown until the Cell Index stabilized. Varying amounts of
doxycycline were then added, and the Cell Index was monitored for 72 h. All
experiments were performed in 3 biological replicates in sets of triplicates. For each
round, cells were concomitantly infected and harvested for protein isolation at 72 h
of doxycycline treatment to assess MX2 levels by western blotting. The primary
antibodies used were rabbit anti-MX2 (NBP1-81018, Novus Biologicals), and
mouse anti-GAPDH (sc-51907, Santa Cruz). Uncropped gel images and molecular
weight marker images for western blot analysis are provided for the corresponding
figure in Source Data file.
Differentially expressed genes in MX2-high melanocytes. From the RNA-seq
data of primary melanocytes (n= 106), we profiled differentially expressed genes
(DEGs) between MX2-high (top 25%; n= 28) and MX2-low (bottom 25%; n= 28)
samples. Total counts of mappable reads for each annotated gene (GENCODE v19)
was obtained using featureCounts from Rsubread package69. The SARTools70
workflow was used to perform quality control, apply differential analysis and
generate reports based on the count data from both MX2-high and MX2-low
groups. edgeR71 was selected as the statistical methodology to determine differ-
ential expression based on the negative binomial distributions. The final DEG list
with criteria FDR < 0.01 and |log2 fold difference| >1 was applied to Ingenuity
Pathway Analysis (IPA). We also performed pairwise gene expression correlation
between MX2 and the rest of 37,854 genes expressed in these 106 primary mela-
nocytes. Bonferroni-correction was applied to P-values of Pearson correlations
(P < 0.05/37,854 or 1.32e−06; equivalent to FDR < 0.05). Genes with expression
levels significantly correlated (FDR < 0.05, N= 377) with those of MX2 were
selected for IPA analysis.
RNA-seq of melanocytes over-expressing MX2. For RNA-seq analyses of MX2
over-expressing melanocytes, primary cultures of melanocytes from three indivi-
duals (C23, C29, and C53) were selected based on their low basal MX2 expression
levels. Cells were grown and infected with the lentiviral system using MX2 cDNA
cloned into pINDUCER20 or empty vector as described above. Following drug
selection, cells were treated with 0 or 100 ng/ml doxycycline (total of three con-
ditions for each cell line: 0 or 100 ng/ml doxycycline for pINDUCER20-MX2
infected cells, and 100 ng/ml doxycycline treatment for empty vector infected cells)
for 72 h before being harvested for RNA and protein isolation. For each cell line,
three separate infections (biological replicates) were performed and sequenced for
transcriptome analysis (total of 27 samples sequenced: 3 conditions, 3 cell lines,
and 3 biological replicates). Western blotting was performed for each cell line to
estimate the level of MX2 induction. For a short-term induction experiment in C23
melanocytes, varying induction times (3, 6, 24, and 72 h) were tested using 100 ng/
ml doxycycline, and 6 h was selected as a time point for RNA-seq analysis based on
MX2 induction levels by western blotting. C23 cells treated with 100 ng/ml dox-
ycycline were collected at 6 h and 72 h timepoints with matched controls without
treatment in three biological replicates. Total RNA was isolated in the same way as
previously described24. Sequencing library was constructed following Illumina
TruSeq Standard mRNA Library protocol. 150 bp paired-end sequencing was
performed on NovaSeq 6000 to achieve at least 50 million reads per sample (range
53.0–82.4 M). FASTQ raw data was received and quality control was performed by
the MultiQC RNA-Seq module72 (https://multiqc.info). Quasi-mapping algorithm
Salmon73 was used to provide fast and bias-aware quantification of transcript
expression using GENCODE human transcripts database (release 29). A principal
component analysis was performed based on the expression qualification, and
based on the results, differentially expressed genes (DEGs) were calculated with
DESeq274 adjusting for cell line, biological replicate, and library construction batch.
The expression threshold FDR < 0.1 was recognized as DEGs after MX2 over
expression by comparing pINDUCER20-MX2-infected cells with (100 ng/ml) or
without doxycycline treatment. The list of significant DEGs was analyzed using
IPA for pathway enrichment analysis. Threshold of P < 0.05 and non-zero z-scores
were used for identifying significantly enriched pathways. DEG analysis of cells
infected with empty vector followed by 100 ng/ml doxycycline treatment vs. those
infected with pINDUCER20-MX2 with no treatment was performed as a control.
IPA analysis using DEGs from this control analysis (1838 genes at FDR < 0.01
cutoff) did not overlap in the same direction of change with the main pathways
enriched by MX2 overexpression except for Apelin Endothelial Signaling Pathway
(Supplementary Table 12 and 16).
Zebrafish melanoma model. The MX2 open reading frame was cloned under the
control of the melanocyte-specific mitfa promoter into the miniCoopR expression
vector43. Tg(mitfa:BRAFV600E), p53−/−, mitfa−/− embryos were injected at the one
cell stage with either miniCoopRmitfa:MX2 or miniCoopRmitfa:EGFP (as a negative
control). Embryos were sorted for melanocyte rescue at 5 days post fertilization (dpf)
and raised to adulthood. Tumor formation was monitored weekly between weeks 10
and 19 post-injection. There were no observable differences between the negative
control and MX2 group in melanocyte rescue efficiency or overall pigmentation of 5
dpf larvae. Representative pictures of adult fish were taken at week 10 post-injection.
Three independent experiments of different sample sizes were performed by inde-
pendent injections of DNA constructs replicating similar results. Kaplan-Meier sur-
vival curve was plotted using the combined data from these three sets, and P-value
was calculated using log-rank test. Pigmentation, size, and numbers of melanomas per
fish were qualitatively assessed at median onset in the two groups. Data from the three
independent experimental sets were combined and P-values were calculated using
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chi-square test. For histology analyses, zebrafish were euthanized at 20 weeks of age,
and fixed in 4% paraformaldehyde overnight at 4 °C. Paraffin embedding, sectioning,
hematoxylin and eosin (H&E) staining were performed according to standard tech-
niques by the Brigham & Women’s Hospital Pathology Core. Immunohistochemistry
was performed on the Leica Biosystems Bond III automated staining platform.
Phospho-Histone H3 (Ser10) Antibody (#9701, Cell Signaling Technologies, Danvers,
MA) was run at 1:500 dilution using the Leica Biosystems Refine Detection Kit with
citrate antigen retrieval, after bleaching of the melanin pigment. Histologic sections
were imaged using an Olympus BX41 microscope with an Olympus DP70 camera. p-
H3 foci were counted on 7 distinct tumor areas per fish for a total surface of 1mm2.
Zebrafish were handled humanely according to our vertebrate animal protocol that
implements the principles of replacement, reduction, and refinement (‘three Rs’), has
been approved by Boston Children’s Hospital Animal Care Committee, and includes
detailed experimental procedures for all in vivo experiments described in this paper.
Statistical analyses. All cell-based experiments were repeated at least three times
with separate cell cultures. When a representative set is shown, replicate experi-
ments displayed similar patterns. For all plots, individual data points are shown
with the median or mean, range (maximum and minimum), and 25th and 75th
percentiles (where applicable). The statistical method, number of data points, and
number and type of replicates are indicated in each figure legend.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The sequencing data generated during this study (MPRA sequencing and RNA-seq data)
are deposited in Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) as a
SuperSeries under the accession number GSE129250 [https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE129250]. A complete list of oligo sequences for MPRA libraries
and complete processed MPRA data can be found in Supplementary Data 7, as well as in
the Source Data. Melanocyte eQTL data and RNA-seq expression data from 106
individuals are available through the database of Genotypes and Phenotypes (dbGAP,
https://www.ncbi.nlm.nih.gov/gap) under accession number phs001500.v1.p1 [https://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001500.v1.p1]. The
source data underlying Figs. 1b, 2b–d, 3–5, 6b, c, f and Supplementary Figs. 3–6, 7a, b, 8,
9a, b, d, 10b–f, 11–16, 18, 19a, c, d, and 20g are provided as a Source Data file. The YY1
Hi-ChIP data presented in Supplementary Fig. 16 was download from the NCBI GEO
database with accession number GSE99519 [https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE99519]. Data from the 2015 melanoma GWAS meta-analysis performed
by Law and colleagues1 was obtained and is available from the corresponding authors of
that manuscript (Matthew Law, Matthew.Law@qimrberghofer.edu.au; or Mark Iles, M.
M.Iles@leeds.ac.uk). All other data is available in the Article, Supplementary Information
or available from the authors upon request.
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